Ascentage's IND Accepted in US for Inhibitor of Apoptosis Blocker

Ascentage Pharma, a China-US company, reported the US FDA accepted its IND submission to begin clinical trials of APG-1387, a novel small molecule targeting pathways that inhibit apoptosis. Ascentage hopes to test the candidate in patients with advanced solid tumors and hematologic malignancies. If approved for human testing, APG-1387 will be the second of Ascentage's apoptosis-promoting candidates to start US and China clinical trials. Ascentage is headquartered in Hong Kong with an R&D lab in Shanghai and a lab-manufacturing facility in Taizhou's China Medical City . More details.... Share this with colleagues: // //